Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AA
MCID: ALP009
MIFTS: 59

Alopecia Areata (AA)

Categories: Immune diseases, Mental diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Alopecia Areata

About this section

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 74 20 43 54 6 44 15 17 71 32
Alopecia Circumscripta 20 43
Cazenave's Vitiligo 20 71
Jonston's Alopecia 20 71
Marginal Alopecia 20 71
Celsus' Vitiligo 20 71
Diffuse Alopecia 20 71
Patchy Alopecia 20 6
Alopecia Celsi 20 71
Pseudopelade 71 32
Aa 20 43
Circumscribed Alopecia 12
Alopecia Cicatrisata 20
Alopecia 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:986
ICD9CM 34 704.01
MeSH 44 D000506
SNOMED-CT 67 201131001
ICD10 32 L63 L63.9 L66.0
UMLS 71 C0002170 C0002171 C0086873 more
Sources

Summaries for Alopecia Areata

About this section
MedlinePlus Genetics : 43 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.In most people with alopecia areata, hair falls out in small, round patches, leaving coin-sized areas of bare skin. This patchy hair loss occurs most often on the scalp but can affect other parts of the body as well. Uncommonly, the hair loss involves the entire scalp (in which case the condition is known as alopecia totalis) or the whole body (alopecia universalis). Other rare forms of alopecia areata, which have different patterns of hair loss, have also been reported.Alopecia areata affects people of all ages, although it most commonly appears in adolescence or early adulthood. Hair loss occurs over a period of weeks. The hair usually grows back after several months, although it may fall out again. In some cases, unpredictable cycles of hair loss followed by regrowth can last for years. In addition to hair loss, some affected individuals have fingernail and toenail abnormalities, such as pits on the surface of the nails.The hair loss associated with alopecia areata is not painful or disabling. However, it causes changes in a person's appearance that can profoundly affect quality of life and self-esteem. In some people, the condition can lead to depression, anxiety, and other emotional or psychological issues.

MalaCards based summary : Alopecia Areata, also known as alopecia circumscripta, is related to alopecia universalis congenita and alopecia, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is AA1 (Alopecia Areata 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Latanoprost and Bimatoprost have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and t cells, and related phenotypes are digestive/alimentary and hematopoietic system

Disease Ontology : 12 An autoimmune disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

GARD : 20 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair.

Wikipedia : 74 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Sources

Related Diseases for Alopecia Areata

About this section

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 690)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 32.9 ULBP3 KLRK1 IL2 AIRE
2 alopecia 32.8 TNF IL4 IL2 IFNG CTLA4 AIRE
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.9 PTPN22 IFNG CTLA4 AIRE
4 vitiligo-associated multiple autoimmune disease susceptibility 1 31.8 PTPN22 IL2 ICOSLG CTLA4 AIRE
5 dermatitis, atopic 31.7 TNF IL4 IL2RA IL2 IL1A IFNG
6 thyroiditis 31.3 TNF PTPN22 IL4 IL2 IFNG CTLA4
7 lupus erythematosus 31.2 TNF PTPN22 IFNG CTLA4
8 folliculitis 31.1 IL4 IL2RA IFNG
9 severe combined immunodeficiency 31.1 IL4 IL2RA IL2 IFNG
10 hashimoto thyroiditis 31.1 PTPN22 IL4 IL2RA IFNG ICAM1 CTLA4
11 contact dermatitis 31.0 TNF IL4 IL2 IL1R1 IL1A IFNG
12 skin disease 31.0 TNF IL4 IL2 IL1A IFNG ICOSLG
13 dermatitis 31.0 TNF IL4 IL2 IL1A IFNG ICAM1
14 candidiasis 31.0 TNF IL4 IL2 IFNG AIRE
15 lichen planus 31.0 TNF IL4 IL2 IFNG ICAM1 GZMB
16 myasthenia gravis 30.9 TNF IL4 IL2 IFNG CTLA4 AIRE
17 rhinitis 30.9 TNF IL4 IFNG ICOSLG ICAM1
18 purpura 30.8 TNF IL4 IFNG
19 hair disease 30.8 TNF IL4 IL2 ICOSLG CTLA4 AIRE
20 irritant dermatitis 30.8 TNF IL4 IL1A
21 exanthem 30.8 TNF IL2 IFNG ICOSLG CTLA4
22 cutaneous lupus erythematosus 30.8 TNF IFNG ICAM1 CTLA4
23 psoriasis 30.8 TNF PTPN22 IL4 IL2RA IL2 IL1R1
24 allergic contact dermatitis 30.8 TNF IL4 IL2RA IL1RN IL1R1 IFNG
25 psoriatic arthritis 30.7 TNF PTPN22 IL4 IL2 IL1RN IL1A
26 autoimmune disease 30.7 TNF PTPN22 KLRK1 IL4 IL2RA IL2
27 chronic spontaneous urticaria 30.7 TNF IL2 IFNG
28 spondylitis 30.6 TNF IFNG ICOSLG
29 food allergy 30.6 TNF IL4 IFNG CTLA4
30 somatoform disorder 30.6 IL4 IL2RA IL1RN IL1A
31 latent autoimmune diabetes in adults 30.6 PTPN22 CTLA4
32 tonsillitis 30.6 TNF IL4 IL2 IL1A IFNG
33 chronic graft versus host disease 30.6 IL2RA IL1A IFNG
34 ulcerative colitis 30.6 TNF IL4 IL2 IL1RN IL1R1 IFNG
35 conjunctivitis 30.6 TNF IL4 IL2 IFNG ICAM1
36 lymphopenia 30.5 PTPN22 IL4 IL2RA IL2 IFNG CTLA4
37 chronic mucocutaneous candidiasis 30.5 TNF PTPN22 IL4 IL2RA IL2 IFNG
38 hypoadrenocorticism, familial 30.5 PTPN22 CTLA4 AIRE
39 hypereosinophilic syndrome 30.5 IL4 IL2RA IL2 IFNG
40 systemic scleroderma 30.5 TNF IL4 IFNG ICOSLG
41 tuberculoid leprosy 30.5 IL2RA IL2 IFNG
42 pemphigoid 30.5 TNF IL4 IFNG
43 temporal arteritis 30.5 TNF PTPN22 IL2 IL1RN IFNG CTLA4
44 mycosis fungoides 30.5 IL2RA IL2 IFNG GZMB CTLA4
45 acquired immunodeficiency syndrome 30.5 TNF IL2RA IL2 IFNG ICAM1
46 spondyloarthropathy 1 30.5 TNF IL1RN IL1R1 ICOSLG
47 crohn's colitis 30.5 TNF IL2 IFNG
48 herpes zoster 30.4 TNF IL2 IFNG ICOSLG
49 atopic keratoconjunctivitis 30.4 IL4 IL2 IFNG
50 adult t-cell leukemia 30.4 IL4 IL2RA IL2 ICAM1 CTLA4

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata
Sources

Symptoms & Phenotypes for Alopecia Areata

About this section

UMLS symptoms related to Alopecia Areata:


pruritus, exanthema

MGI Mouse Phenotypes related to Alopecia Areata:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.21 AIRE CTLA4 ICAM1 IFNG IKZF4 IL1R1
2 hematopoietic system MP:0005397 10.18 AIRE CTLA4 ICAM1 IFNG IKZF4 IL1A
3 immune system MP:0005387 10.17 AIRE CTLA4 ICAM1 IFNG IKZF4 IL1A
4 endocrine/exocrine gland MP:0005379 10.1 AIRE CTLA4 ICAM1 IFNG IL1R1 IL2
5 integument MP:0010771 9.91 CTLA4 ICAM1 IFNG IL1A IL1R1 IL1RN
6 liver/biliary system MP:0005370 9.76 AIRE CTLA4 IFNG IL1R1 IL2 IL4
7 neoplasm MP:0002006 9.5 AIRE ICAM1 IFNG IL1A IL1R1 IL2
8 respiratory system MP:0005388 9.32 AIRE CTLA4 IFNG IL1R1 IL2 IL2RA
Sources

Drugs & Therapeutics for Alopecia Areata

About this section

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
2
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6 Orange Approved Phase 4
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
13
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
16
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Cetirizine Approved Phase 4 83881-51-0 2678
19
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
22
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
23 Dermatologic Agents Phase 4
24 Ophthalmic Solutions Phase 4
25 Anesthetics Phase 4
26 Antiprotozoal Agents Phase 4
27 Antimalarials Phase 4
28 Protective Agents Phase 4
29 Gastrointestinal Agents Phase 4
30 Methylprednisolone Acetate Phase 4
31 Neuroprotective Agents Phase 4
32 Antineoplastic Agents, Hormonal Phase 4
33 Antiemetics Phase 4
34 Sodium Channel Blockers Phase 4
35 Anesthetics, Local Phase 4
36 Anti-Arrhythmia Agents Phase 4
37 Anti-Asthmatic Agents Phase 4
38 Respiratory System Agents Phase 4
39 Betamethasone sodium phosphate Phase 4
40 Betamethasone-17,21-dipropionate Phase 4
41 Betamethasone benzoate Phase 4
42 Betamethasone Valerate Phase 4 2152-44-5
43 Analgesics, Non-Narcotic Phase 4
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4
45 Analgesics Phase 4
46 N-monoacetylcystine Phase 4
47 Neurotransmitter Agents Phase 4
48 Anti-Allergic Agents Phase 4
49 Histamine Antagonists Phase 4
50 Histamine H1 Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
4 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
5 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
6 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
7 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
8 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
9 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
10 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed NCT03800979 Phase 4 Tofacitinib
11 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
12 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
13 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
14 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
15 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
16 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
17 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
18 Modified SALT Score for Assessment of Alopecia Areata Recruiting NCT04412148 Phase 4 Triamcinolone Acetonide
19 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
20 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
21 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
22 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Active, not recruiting NCT04228029 Phase 4 Intralesional Steroid Injection
23 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
24 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
25 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
26 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
27 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
28 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
29 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
30 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
31 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
32 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
33 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
34 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
35 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
36 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
37 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
38 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
39 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
40 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
41 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
42 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
43 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
44 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
45 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
46 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
47 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
48 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
49 The Derm Aid Study Completed NCT04249128 Phase 3
50 Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer Recruiting NCT03711877 Phase 3

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 71 / NDF-RT 51 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia areata

Sources

Genetic Tests for Alopecia Areata

About this section
Sources

Anatomical Context for Alopecia Areata

About this section

MalaCards organs/tissues related to Alopecia Areata:

40
Skin, Thyroid, T Cells, Brain, Myeloid, Pituitary, Breast
Sources

Publications for Alopecia Areata

About this section

Articles related to Alopecia Areata:

(show top 50) (show all 4097)
# Title Authors PMID Year
1
Immunopathogenesis of folliculitis decalvans: clues in early lesions. 54 61
18794044 2008
2
[Regulatory effect of procyanidins on the expressions of interferon-gamma, interleukin-12 and transcription factor T-bet mRNA in peripheral blood mononuclear cell of patients with alopecia areata]. 54 61
19123327 2008
3
The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. 54 61
18616774 2008
4
Genetic analysis of autoimmune regulator haplotypes in alopecia areata. 61 54
18194361 2008
5
In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis. 54 61
17021766 2007
6
Investigation of the p.Ser278Arg polymorphism of the autoimmune regulator (AIRE) gene in alopecia areata. 54 61
16774540 2006
7
[Alopecia areata universalis and disseminated mollusca contagiosa in atopic dermatitis. Hair re-growth during treatment with interferon gamma--therapeutic effect or coincidence?]. 54 61
15892847 2005
8
[Interferon-gamma and neopterin in alopecia areata]. 54 61
16052058 2005
9
Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. 61 54
15037212 2004
10
The beneficial and detrimental effects of linoleic acid on autoimmune disorders. 54 61
15115315 2004
11
Interferon-gamma in alopecia areata. 61 54
14965793 2004
12
Therapy of alopecia areata: on the cusp and in the future. 54 61
14582675 2003
13
Selective expression of chemokine monokine induced by interferon-gamma in alopecia areata. 54 61
14632215 2003
14
Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. 61 54
12624779 2003
15
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. 54 61
12542742 2002
16
Epidemiology and genetics of alopecia areata. 54 61
12190641 2002
17
Interleukin-1 receptor antagonist allele 2 and familial alopecia areata. 54 61
11841553 2002
18
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction. 61 54
11841485 2002
19
Association analysis of IL1A and IL1B variants in alopecia areata. 61 54
11703512 2001
20
Role of cytotoxic T cells in chronic alopecia areata. 61 54
10620125 2000
21
Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. 61 54
10674367 1999
22
Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. 54 61
10417620 1999
23
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. 54 61
9421466 1998
24
IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha. 61 54
9266024 1997
25
Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. 61 54
8977716 1996
26
Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. 61 54
8967784 1996
27
Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. 54 61
8721483 1996
28
An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. 54 61
7738374 1995
29
Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. 54 61
8077705 1994
30
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines. 54 61
7506926 1993
31
Response of grafts from patients with alopecia areata transplanted onto nude mice, to administration of interferon-gamma. 54 61
8095867 1993
32
Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. 54 61
1708803 1991
33
Oral minoxidil treatment for hair loss: A review of efficacy and safety. 61
32622136 2021
34
Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. 61
31389731 2021
35
Putative therapeutic mechanisms of simvastatin in the treatment of alopecia areata. 61
32278796 2021
36
Drug-induced alopecia areata? 61
32681530 2021
37
An open-label study evaluating the efficacy of abatacept in alopecia areata. 61
33045294 2021
38
Use of vibrating anesthetic device reduces the pain of mesotherapy injections: A randomized split-scalp study. 61
32640097 2021
39
Expression of survivin and p53 genes in patients with alopecia areata: A case-control study. 61
32951213 2021
40
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. 61
31693426 2021
41
Rapidly progressive alopecia areata totalis in a Covid-19 patient, unresponsive to tofacitinib. 61
33587766 2021
42
Increased Alopecia Areata Risk in Children with Attention-Deficit/Hyperactivity Disorder and the Impact of Methylphenidate Use: A Nationwide Population-Based Cohort Study. 61
33535410 2021
43
Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. 61
32376430 2021
44
Posttraumatic stress disorder and the associated risk of autoimmune skin diseases: A nationwide population-based cohort study. 61
33587564 2021
45
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
46
Lessons Learned from the First Decade of Laser-Assisted Drug Delivery. 61
33464473 2021
47
Are drug treatment strategies really effective against alopecia areata? 61
33280456 2021
48
Efficacy and predictive factors of cyclosporine a in alopecia areata: a systematic review with meta-analysis. 61
33555953 2021
49
Flag sign: the trichoscopic feature of white hair phenomenon in alopecia areata. 61
32762090 2021
50
Prevalence of cardiac and metabolic diseases among patients with alopecia areata. 61
32780884 2021
Sources

Variations for Alopecia Areata

About this section

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TRPS1 NM_014112.5(TRPS1):c.2794G>A (p.Ala932Thr) SNV Likely pathogenic 374202 rs1057518972 8:116430587-116430587 8:115418359-115418359
2 NDC80 GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168) copy number loss Uncertain significance 523239 18:1345040-3479168
Sources

Expression for Alopecia Areata

About this section
Search GEO for disease gene expression data for Alopecia Areata.
Sources

Pathways for Alopecia Areata

About this section

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.02 ULBP3 TNF PTPN22 KLRK1 IL4 IL2RA
2
TGF-Beta Pathway 63
Show member pathways
 13.55 TNF IL4 IL2RA IL2 IL1R1 IL1A
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.38 TNF IL4 IL2RA IL2 IL1RN IL1R1
4
PAK Pathway 63
Show member pathways
 13.31 TNF PTPN22 IL4 IL2RA IL2 IL1R1
5
IL-2 Pathway 63
Show member pathways
 13.23 TNF IL4 IL2RA IL2 IL1R1 IL1A
6
Measles 36
Show member pathways
 12.86 TNF IL2RA IL2 IL1A IFNG ICAM1
7
Immune response NFAT in immune response 23
Show member pathways
 12.66 TNF IL4 IL2RA IL2 IFNG ICOSLG
8
T cell receptor signaling pathway 36
Show member pathways
 12.64 TNF IL4 IL2 IL1A IFNG CTLA4
9
Th17 cell differentiation 36
Show member pathways
 12.63 TNF IL4 IL2RA IL2 IL1R1 IL1A
10
Allograft rejection 36 1
Show member pathways
 12.6 TNF IL4 IL2RA IL2 IL1A IFNG
11
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.53 ULBP3 TNF KLRK1 IL4 IL2 IFNG
12
Apoptosis Pathway 70
Show member pathways
 12.44 IL2RA IL2 IL1R1 IL1A
13
JAK-STAT signaling pathway 36
Show member pathways
 12.42 IL4 IL2RA IL2 IFNG
14
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.4 IL2RA IL2 ICOSLG CTLA4
15
Human T-cell leukemia virus 1 infection 36
12.38 TNF IL2RA IL2 IL1R1 ICAM1
16
Folate Metabolism 1
Show member pathways
 12.37 TNF IL4 IL2 IFNG ICAM1
17
Toll Comparative Pathway 63
Show member pathways
 12.32 TNF IL1R1 IL1A IFNG
18
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.3 TNF IL4 IL2RA IL2 IL1A IFNG
19
Toxoplasmosis 36
Show member pathways
 12.28 TNF IL4 IL1A IFNG
20
Bacterial infections in CF airways 23
Show member pathways
 12.21 TNF IL4 IL1R1 IFNG
21
Fluid shear stress and atherosclerosis 36
12.14 TNF IL1R1 IL1A IFNG ICAM1
22
NF-kappaB Signaling 4
12.12 TNF PTPN22 IL4 IL2RA IL2 IL1RN
23
Osteoclast differentiation 36
12.09 TNF IL1R1 IL1A IFNG
24
MAPK Pathway 70
Show member pathways
 12.07 IL2RA IL2 IL1R1 IL1A
25
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.05 TNF KLRK1 IL4 IL2RA IL2 IFNG
26
Interleukin-4 and 13 signaling 65
12.02 TNF IL4 IL1A ICAM1
27
IL12-mediated signaling events 1
Show member pathways
 12.02 IL4 IL2RA IL2 IL1R1 IFNG GZMB
28
Hematopoietic cell lineage 36
11.96 TNF IL4 IL2RA IL1R1 IL1A
29
Spinal Cord Injury 1
11.94 TNF IL4 IL2 IL1R1 IL1A IFNG
30
Rheumatoid arthritis 36
11.92 TNF IL1A IFNG ICAM1 CTLA4
31
Th17 Differentiation Pathway 64
Show member pathways
 11.91 IL4 IL1R1 IFNG GZMB
32
Glucocorticoid receptor regulatory network 1
11.85 IL4 IL2 IFNG ICAM1
33
Th1 Differentiation Pathway 64
Show member pathways
 11.77 TNF IL2 IFNG
34
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.76 TNF IL4 IL2RA IL2 IFNG CTLA4
35
Dendritic Cells Developmental Lineage Pathway 64
11.75 TNF IL2 IFNG
36
Commom Cytokine Receptor G Chain Siganaling Pathway 66
11.74 IL4 IL2RA IL2
37
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.73 TNF IL2 IL1A IFNG ICAM1
38
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.71 IL4 IL2RA IL2
39
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.71 TNF IL2RA IL2 IFNG GZMB
40
IgA-Producing B Cells in the Intestine 64
11.66 TNF IL4 IL2RA ICOSLG ICAM1 CTLA4
41
Malaria 36
11.61 TNF KLRK1 IFNG ICAM1
42
Transcription_NF-kB signaling pathway 23
11.6 TNF IL1R1 IL1A
43
Photodynamic therapy-induced AP-1 survival signaling. 1
11.58 TNF IL2 IFNG
44
Th2 Differentiation Pathway 64
11.56 IL4 IL2RA IL2 IFNG
45
Aryl Hydrocarbon Receptor Pathway 1
11.54 TNF IL2 IFNG
46
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.51 TNF IL1A IFNG
47
African trypanosomiasis 36
11.43 TNF IFNG ICAM1
48
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.43 TNF IL2RA IL2 IFNG GZMB
49
Interleukin-10 signaling 65
11.42 TNF IL4 IL1RN IL1R1 IL1A ICAM1
50
Inflammatory Response Pathway 1
11.4 IL4 IL2RA IL2 IFNG
Sources

GO Terms for Alopecia Areata

About this section

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ULBP3 TNF IL4 IL2 IL1RN IL1A
2 external side of plasma membrane GO:0009897 9.23 ULBP3 TNF KLRK1 IL2RA IL1R1 ICOSLG

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.05 TNF PTPN22 IL4 IL1A IFNG
2 immune system process GO:0002376 10.05 ULBP3 PTPN22 KLRK1 IL2RA IL2 ICOSLG
3 adaptive immune response GO:0002250 10.04 KLRK1 IL2 IFNG ICOSLG CTLA4
4 inflammatory response GO:0006954 10.02 TNF IL2RA IL1RN IL1R1 IL1A
5 regulation of immune response GO:0050776 9.93 ULBP3 KLRK1 IL4 ICAM1
6 positive regulation of interleukin-6 production GO:0032755 9.84 TNF IL1A IFNG
7 positive regulation of T cell proliferation GO:0042102 9.8 IL4 IL2RA IL2
8 humoral immune response GO:0006959 9.8 TNF IFNG AIRE
9 positive regulation of cytokine production GO:0001819 9.79 TNF IL1A IFNG
10 T cell costimulation GO:0031295 9.77 KLRK1 ICOSLG CTLA4
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.74 TNF IFNG ICAM1
12 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.71 IL4 IL2 IL1A
13 microglial cell activation GO:0001774 9.7 TNF IL4 IFNG
14 positive regulation of activated T cell proliferation GO:0042104 9.67 IL2RA IL2 ICOSLG
15 negative regulation of amyloid-beta clearance GO:1900222 9.66 TNF IFNG
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL4 IFNG
17 interleukin-2-mediated signaling pathway GO:0038110 9.65 IL2RA IL2
18 negative regulation of T-helper 17 cell differentiation GO:2000320 9.64 IL4 IL2
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 IL4 IL2
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 TNF IL4 IL2 IFNG
21 positive regulation of mononuclear cell migration GO:0071677 9.61 TNF IL4
22 natural killer cell activation GO:0030101 9.61 ULBP3 KLRK1 IL2
23 negative regulation of lymphocyte proliferation GO:0050672 9.6 IL2RA IL2
24 positive regulation of cellular respiration GO:1901857 9.58 IL4 IFNG
25 neuroinflammatory response GO:0150076 9.58 IL4 IFNG
26 positive regulation of T cell differentiation GO:0045582 9.58 IL4 IL2RA IL2
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IFNG
28 positive regulation of interferon-gamma production GO:0032729 9.56 TNF PTPN22 IL2 IL1R1
29 cytokine-mediated signaling pathway GO:0019221 9.56 TNF IL4 IL2RA IL2 IL1RN IL1R1
30 regulation of T cell homeostatic proliferation GO:0046013 9.55 IL2RA IL2
31 natural killer cell mediated cytotoxicity GO:0042267 9.54 ULBP3 KLRK1 GZMB
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
33 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
34 regulation of regulatory T cell differentiation GO:0045589 9.46 IL2RA IL2 IFNG CTLA4
35 immune response GO:0006955 9.36 ULBP3 TNF IL4 IL2RA IL2 IL1RN

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL4 IL2 IL1RN IL1A IFNG
Sources

Sources for Alopecia Areata

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....